Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Targeting the epidermal growth factor receptor in solid tumor malignancies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Actively personalized vaccination trial for newly diagnosed glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Extracranial metastases in glioblastoma-Two case stories

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The epidermal growth factor receptor (EGFR) is over-expressed, as well as mutated, in many types of cancers. In particular, the EGFR variant type III mutant (EGFRvIII) has attracted much attention as it is frequently and exclusively found on many tumor cells, and hence both EGFR and EGFRvIII have been proposed as valid targets in many cancer therapy settings. Different strategies have been developed in order to either inhibit EGFR/EGFRvIII activity or to ablate EGFR/EGFRvIII-positive tumor cells. Drugs that inhibit these receptors include monoclonal antibodies (mAbs) that bind to the extracellular part of EGFR, blocking the binding sites for the EGFR ligands, and intracellular tyrosine kinase inhibitors (TKIs) that block the ATP binding site of the tyrosine kinase domain. Besides an EGFRvIII-targeted vaccine, conjugated anti-EGFR mAbs have been used in different settings to deliver lethal agents to the EGFR/EGFRvIII-positive cells; among these are radio-labelled mAbs and immunotoxins. This article reviews the current status and efficacy of EGFR/EGFRvIII-targeted therapies.
OriginalsprogEngelsk
TidsskriftBioDrugs
Vol/bind26
Udgave nummer2
Sider (fra-til)83-99
Antal sider17
ISSN1173-8804
DOI
StatusUdgivet - 2012

ID: 36890041